Please ensure Javascript is enabled for purposes of website accessibility

OriGene to expand research capability

OriGene Technologies Inc., of Rockville, a privately held developer of genetic research products, said it signed a definitive agreement to acquire all the assets of the Life Science business of SDIX, a provider of biotechnology-based products and services.

SDIX, or Strategic Diagnostics Inc., is a publicly traded company based in Newark, Del. OriGene did not disclose the price of the assets it has agreed to acquire.

In a statement, OriGene said the acquisition, which it expects to close in the second quarter of 2013, will enhance its ability to “continue to continue to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications both in research and diagnostics fields.”